Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
Live Webcast: The formal presentation is scheduled for 4:30 p.m. Pacific Time, and will be accessible via a live webcast, enhancing investor transparency and engagement with the company.
Investor Relations: An archived replay of the webcast will be available on Mesa Labs' Investor Relations website after the presentation, ensuring that investors who cannot attend live can still access key information, thereby improving communication efficiency with stakeholders.
Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries, committed to enhancing product integrity and patient safety, further solidifying its market position.
MLAB
$80.6+Infinity%1D
Analyst Views on MLAB
Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 79.770
Low
115.00
Averages
115.00
High
115.00
Current: 79.770
Low
115.00
Averages
115.00
High
115.00
Wells Fargo
Equal Weight
maintain
$75 -> $83
2025-12-15
New
Reason
Wells Fargo
Price Target
$75 -> $83
2025-12-15
New
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Mesa Labs to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Jefferies
Tycho Peterson
Buy
maintain
$110 -> $115
2025-11-07
Reason
Jefferies
Tycho Peterson
Price Target
$110 -> $115
2025-11-07
maintain
Buy
Reason
Jefferies analyst Tycho Peterson raised the firm's price target on Mesa Labs to $115 from $110 and keeps a Buy rating on the shares following a Q2 report that were "solid" and "a relatively less noisy showing than 1Q results." The firm sees scope for shares to re-rate higher as stability comes back and credibility builds, the analyst tells investors.
Wells Fargo
Underweight -> Equal Weight
upgrade
$100 -> $67
2025-08-07
Reason
Wells Fargo
Price Target
$100 -> $67
2025-08-07
upgrade
Underweight -> Equal Weight
Reason
Wells Fargo upgraded Mesa Labs to Equal Weight from Underweight with a price target of $67, down from $100. The firm believes the recent sharp stock selloff appears overdone in the context of relatively stable fundamentals and clear balance sheet flexibility for Mesa Labs to redeem its outstanding converts due next week. Wells sees a more balanced risk/reward here at about 8-times EBITDA.
Wells Fargo
Brandon Couillard
Underweight
downgrade
$120 -> $100
2025-05-30
Reason
Wells Fargo
Brandon Couillard
Price Target
$120 -> $100
2025-05-30
downgrade
Underweight
Reason
Wells Fargo analyst Brandon Couillard lowered the firm's price target on Mesa Labs to $100 from $120 and keeps an Underweight rating on the shares. The firm notes Q4 revenues were in line, but adjusted EBITDA missed by about $2M, driven by higher-than-expected bonus accrual. Shares traded sharply lower, which Wells attributes to weak Q4 margins.
About MLAB
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
